Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rosuvastatin vs Atorvastatin in Hypercholesterolaemia
NCT00239330Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Jun 2003
- Primary completion
- Feb 2005
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of rosuvastatin in hypercholesterolemia (2 arms), sponsored by AstraZeneca. Primary endpoint: Percentage of subjects reaching EAS LDL-C target goals at 12 weeks. Started Jun 2003; status: completed.
02
Drugs
rosuvastatin
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT00239330.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00239330.